Welcome to our dedicated page for SOHM news (Ticker: $SHMN), a resource for investors and traders seeking the latest updates and insights on SOHM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SOHM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SOHM's position in the market.
Rhea-AI Summary
SOHM, Inc. (SHMN) collaborates with Coastar Therapeutics to advance genome editing technology using innovative drug delivery systems. The partnership aims to enhance gene editing efficiency and safety through the integration of Coastar's red blood cell membrane derived carriers with SOHM's ABBIE genome editing technology, offering new possibilities for gene therapy and precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SOHM, Inc. (OTC PINK: SHMN) announces filing of provisional patent application for ABBIE 'Smart Gene-Editing' platform. The gene-editing market was valued at $5.3 billion in 2023 and is expected to grow to $10.8 billion by 2028. The company aims to resolve off-target gene-editing limitations with ABBIE, utilizing the latest enzymes, guide RNAs, and graphene-based nanomaterials. ABBIE's technology aims to improve precision, reduce immune response, and extend applications beyond human health, revolutionizing genome editing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
-
Rhea-AI Summary
SOHM, Inc. (SHMN) announced its business outlook for 2024, detailing market backgrounds, business strategies, and revenue expectations for its OTC Self-care, Branded Generics, CDMO Services, and Biotech Gene-Editing Kit business units.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
Rhea-AI Summary
SOHM, Inc. (SHMN) announces the opening of a new CDMO GMP manufacturing facility in Carlsbad, California, to meet the growing demand for its pharmaceutical, nutraceutical, and cosmeceutical products. The facility will have an initial daily capacity of 500 gallons and aims to complete the engineering batches produced in the San Diego facility by Q1 2024. The company's strategic plan to enhance production capacity and efficiency aligns with the expanding bio and pharma CDMO market, which is expected to grow to $309 billion by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SOHM, Inc. (OTC PINK: SHMN) announces the launch of 13 new SOHM Nutrients’ Brand Chewables, targeting the global vitamin gummies market. The global vitamins market, valued at $6.84 billion in 2022, is expected to reach $18.76 billion by 2031, with a CAGR of 12.06% between 2023-2031. The new chewables offer bone health, skin health, immune boost, mineral replenishment, and sleep aid, featuring convenience, taste, and sought-after ingredients. They will be available for retail and bulk purchases through Amazon.com and the company’s Direct-to-Consumers Website at competitive prices. Dr. David Aguilar, COO of SOHM, anticipates a significant impact on sales, with plans to announce additional OTC Self-care products launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
-
Rhea-AI Summary
SOHM, Inc. announces collaboration with University of Arizona Center for Innovation to develop ABBIE gene-editing kit technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
Rhea-AI Summary
SOHM, Inc. has acquired ABBIE, a gene-editing platform, positioning itself in the $5.3 billion gene-editing market. The gene-editing market is expected to grow to $10.8 billion by 2028. ABBIE is undergoing development to become high-quality cell engineering kits. Revenue can be generated immediately through licensing and gene-editing kits to be released in 2024. ABBIE is expected to reach in-human trial by 2025. ABBIE was acquired for $10 million from CGA 369. ABBIE's development will be presented at scientific conferences in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
SOHM, Inc. appoints Wm. Dewey Rushing as Vice President-Quality, bringing valuable expertise in pharmaceutical quality validation and compliance. Rushing's experience will be valuable as the company diversifies its portfolio and expands to new markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
SOHM, Inc. appoints Dr. Krishna Bhat as Chief Medical Advisor, bringing valuable expertise in cardiology. Dr. Bhat's experience will support the planned acquisition of ABBIE Technology and its innovative patents, clinical trials, diagnostic kits, and cardiac treatments. Dr. Bhat is a renowned Clinical and Interventional Cardiologist with over 35 years of practice and has authored 16 medical scientific publications. The acquisition of ABBIE Technology and the development of the San Diego plant are expected to create new opportunities and increase revenues for SOHM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
SOHM INC